| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Atherosclerosis and Lipoproteins |
From the Departments of Internal Medicine (J.C., Y.L., H.L., P.L.H., J.L.M.) and Physiology and Biophysics (J.C.), University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, Ark.
Correspondence to J.L. Mehta, MD, PhD, Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences, 4301 W Markham St, Slot 532, Little Rock, AR 72205-7199. E-mail MehtaJL{at}uams.edu
Objective LOX-1, a receptor for oxidized low-density lipoprotein, plays a critical role in atherosclerosis. Its expression is upregulated by pro-atherogenic stimuli, such as angiotensin II (Ang II). In this study, we explored LOX-1 transcriptional promoter activation in response to Ang II in human coronary artery endothelial cells (HCAECs).
Methods and Results We constructed full-length and deletion LOX-1 promoter mutants and examined their activation in response to Ang II in HCAECs. The Ang II (1 µmol/L for 24 hours) markedly induced LOX-1 promoter activity beyond the basal level, and a 116-bp fragment (between nt 2247 and 2131) was necessary for this induction. Within this 116-bp promoter fragment, there is a potential binding motif for transcription factor NF-
B. By EMSA, we observed the activation of NF-
B by Ang II. The critical role of NF-
B in Ang IIinduced LOX-1 promoter activation was confirmed by mutagenesis assay, and further confirmed by blocking NF-
B activation with the NF-
B inhibitor caffeic acid phenethyl ester or NF-
B p65 siRNA.
Conclusion This study strongly suggests that Ang II, by activating NF-
B, induces LOX-1 promoter activation.
In this study, we explored LOX-1 transcriptional promoter activation in response to angiotensin II (Ang II) in human coronary artery endothelial cells. This study strongly suggests that Ang II, by activating NF-
B, induces LOX-1 promoter activation.
Key Words: LOX-1 Ang II oxLDL transcription factor NF-
B oxidative stress
This article has been cited by other articles:
![]() |
C. Hu, A. Dandapat, L. Sun, M. R. Marwali, N. Inoue, F. Sugawara, K. Inoue, Y. Kawase, K.-i. Jishage, H. Suzuki, et al. Modulation of Angiotensin II-Mediated Hypertension and Cardiac Remodeling by Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Deletion Hypertension, September 1, 2008; 52(3): 556 - 562. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Frohlich Excitement of Clinical Investigation: New Basic Mechanisms of Action After Drug Introduction Hypertension, September 1, 2008; 52(3): 465 - 466. [Full Text] [PDF] |
||||
![]() |
A. Bukowska, L. Schild, G. Keilhoff, D. Hirte, M. Neumann, A. Gardemann, K. H. Neumann, F.-W. Rohl, C. Huth, A. Goette, et al. Mitochondrial Dysfunction and Redox Signaling in Atrial Tachyarrhythmia Experimental Biology and Medicine, May 1, 2008; 233(5): 558 - 574. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Hu, A. Dandapat, and J. L Mehta Angiotensin II Induces Capillary Formation From Endothelial Cells Via the LOX-1 Dependent Redox-Sensitive Pathway Hypertension, November 1, 2007; 50(5): 952 - 957. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |